Skip to main content

Advertisement

Table 4 In vitro activities of 11 antibiotics against S. pneumoniae clinical isolates from SOT recipients

From: Prevalence and clinical impact of Streptococcus pneumoniae nasopharyngeal carriage in solid organ transplant recipients

Antibiotic CLSI breakpointsa (% of isolates) PK/PD
Susceptible Intermediate Resistant Susceptibility (% of isolates) Breakpoint (μg/ml)
O. Penicillin 39.39 51.52 9.09 39.39 ≤0.06
I. Penicillin 100 0 0 100 ≤2
Amoxicillin 87.88 9.09 3.03 87.88 ≤2
Cefotaxime 100 0 0 100 ≤1
Ceftriaxone 96.97 3.03 0 96.97 ≤1
Azithromycin 53.03 16.67 30.30 53.03 ≤0.5
Erythromycin 66.67 3.03 30.30 66.67 ≤0.25
Clarithromycin 71.21 0 28.79 71.21 ≤0.25
Levofloxacin 75.76 24.24 0 75.76 ≤2
Vancomycin 100 0 0 100 ≤1
Trimethoprim-sulfamethoxazole 53.03 16.67 30.30 53.03 ≤0.5
  1. Abbreviations: O oral, I intravenous
  2. aThe CLSI breakpoints used were ≤ 0.06 mg/L (susceptible), 0.12 to 1 mg/L (intermediate), and ≥ 2 mg/L (resistant) for oral penicillin and ≤ 2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for intravenous penicillin; ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for amoxicillin; ≤1 mg/L (susceptible), 2 mg/L (intermediate), and ≥ 4 mg/L (resistant) for cefotaxime and ceftriaxone; ≤0.5 mg/L (susceptible), 1 mg/L (intermediate), and ≥ 2 mg/L (resistant) for azithromycin; ≤0.25 mg/L (susceptible), 0.5 mg/L (intermediate), and ≥ 1 mg/L (resistant) for erythromycin and clarithromycin; ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥ 8 mg/L (resistant) for levofloxacin; ≤1 mg/L (susceptible) for vancomycin; and ≤ 0.5 mg/L (susceptible), 1–2 mg/L (intermediate), and ≥ 4 mg/L (resistant) for trimethoprim-sulfamethoxazole